The European Society for Medical Oncology (ESMO) announced today that the recipient of the 2025 ESMO Breast Cancer Award is Gabriel N. Hortobagyi, Professor of Medicine in the Department of Breast Medical Oncology at The University of Texas M.D. Anderson Cancer Center, USA. Hortobagyi is recognised for his exceptional contributions to the breast cancer field, from his role in the introduction of anthracyclines, neoadjuvant chemotherapy, and combined modality therapy in the 1970s, to his work with taxanes and bisphosphonates in the 1990s, and, more recently, his development of everolimus, alpelisib, and ribociclib, among other achievements.
Hortobagyi will deliver his award lecture titled: “Development of targeted therapies for HR+ breast cancer” during the opening session of the ESMO Breast Cancer 2025 congress, on Wednesday, 14 May.